Drug Interaction Report
1 potential interaction and/or warning found for the following 2 drugs:
- Decadron-LA (dexamethasone)
- pipecuronium
Interactions between your drugs
dexAMETHasone pipecuronium
Applies to: Decadron-LA (dexamethasone), pipecuronium
MONITOR: Corticosteroids may inhibit or enhance the action of nondepolarizing skeletal muscle relaxants. The mechanism is unknown. In addition, the risk of myopathy may be increased after long-term use of neuromuscular blocking agents and corticosteroids.
MANAGEMENT: Patients should be closely monitored for altered neuromuscular blockade and signs of myopathy. Dose adjustments of the muscle relaxant may be required. The benefit-to-risk ratio should be considered and the duration of administration of the neuromuscular blocking agent should be limited as much as clinically feasible.
References (8)
- Parr SM, Galletly DC, Robinson BJ (1991) "Betamethasone-induced resistance to vercuronium: a potential problem in neurosurgery." Anaesth Intensive Care, 19, p. 103-5
- Laflin MJ (1977) "Interaction of pancuronium and corticosteroids." Anesthesiology, 47, p. 471-2
- Meyers EF (1977) "Partial recovery from pancuronium neuromuscular blockade following hydrocortosone administration." Anesthesiology, 46, p. 148-50
- (2001) "Product Information. Zemuron (rocuronium)." Organon
- (2001) "Product Information. Norcuron (vecuronium)." Organon
- Cerner Multum, Inc. "UK Summary of Product Characteristics."
- Agencia Española de Medicamentos y Productos Sanitarios Healthcare (2008) Centro de información online de medicamentos de la AEMPS - CIMA. https://cima.aemps.es/cima/publico/home.html
- (2022) "Product Information. Betamethasone Acet-Betamethasone Na Phos (betamethasone)." Exela Pharma
Drug and food interactions
No alcohol/food interactions were found with the drugs in your list. However, this does not necessarily mean no food interactions exist. Always consult your healthcare provider.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Entyvio
Entyvio (vedolizumab) is used to treat ulcerative colitis (UC) and Crohn's disease, reducing ...
Benlysta
Benlysta infusion is used to treat active systemic lupus erythematosus (SLE) and active lupus ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Carvykti
Carvykti (ciltacabtagene autoleucel) is used for the treatment of relapsed or refractory multiple ...
Abecma
Abecma is a CAR T cell therapy used to treat relapsed refractory multiple myeloma (RRMM); it is a ...
Nplate
Nplate is used to prevent bleeding episodes in people with chronic immune thrombocytopenic purpura ...
Otezla
Otezla (apremilast) is used to treat plaque psoriasis, psoriatic arthritis, and oral ulcers ...
Skyrizi
Skyrizi (risankizumab) is used to treat plaque psoriasis, psoriatic arthritis, ulcerative colitis ...
Tecvayli
Tecvayli (teclistamab) is a treatment for relapsed or refractory multiple myeloma. Includes ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.